Why the PYC Therapeutics (ASX:PYC) share price is up 11% today

The PYC Therapeutics share price is higher today after the company announced that it has added another drug to its pipeline.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Today, the PYC Therapeutics (ASX: PYC) share price is up 11.11% to 20 cents at the time of writing. The surge in the PYC Therapeutics share price came after the company added a new drug to its pipeline.

row of piggy banks with large one receiving injection representing rising Immutep share price

Image source: Getty Images

What was the announcement?

PYC Therapeutics has added a new drug to its pipeline for the treatment of 'Autosomal Dominant Optic Atrophy' (ADOA) caused by mutations in the OPA1 gene. The disease causes blindness and, according to PYC Therapeutics, it affects 1 in every 30,000 people. The company has also advised that no treatment is currently available for this type of ADOA, with those suffering from the disease losing vision rapidly in childhood and early adolescence. 

The new drug, known as VP-002, works by correcting a protein deficiency in cells which are affected by the OPA1 type of ADOA. The company expects the drug to have a rapid path into clinical development due to synergies across its existing drug programs. The drug will utilise the same proprietary delivery method as other drugs in PYC Therapeutics' pipeline. The company has stated that it is in the pre-clinical stages of developing a technology for the delivery of drugs directly into the retina for blinding eye diseases. According to PYC Therapeutics, it will also use its existing 'backbone' chemistry to develop VP-002.

About the PYC Therapeutics share price

PYC Therapeutics is a pharmaceutical company which is developing a range of drugs that can be injected directly into cells. The drug maker has been listed on the ASX since 2005.

On 6 October 2020, PYC Therapeutics made an announcement that it had added another drug to its pipeline. The new drug is intended to treat diabetes-related retinopathy and age-related macular degeneration which, according to the company, are the two leading causes of blindness globally.

In the year to 30 June 2020, PYC Therapeutics posted a loss of 0.26 cents per share. The company had $7.24 million cash on hand at 30 June 2020.

The PYC Therapeutics share price is up 365.12% since its 52-week low of 4.3 cents and is up 233.33% since the beginning of the year. The PYC Therapeutics share price is up 233.33% since this time last year.

Motley Fool contributor Chris Chitty has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »